INSM

INSMED Inc. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. INSMED Inc. is a global biopharmaceutical company focused on Respiratory, Immunology & Inflammation, and Neuro & Other Rare therapeutic areas. The company's commercial portfolio includes ARIKAYCE (for MAC lung disease) and BRINSUPRI (for non-cystic fibrosis bronchiectasis), which received US approval in August 2025 and EU/UK approvals in late 2025/early 2026. The company operates as a single segment and continues to fund significant R&D activities for its pipeline, including TPIP and INS1148.

Key Financial Metrics

Note: Working Capital calculated as Total Current Assets minus Total Current Liabilities.

Material Changes vs. Prior Period

• Revenue Surge: Net product revenues increased by 229.6% to $306.0 million, driven primarily by $207.2 million in US sales of BRINSUPRI following its August 2025 launch. ARIKAYCE revenue grew 5.7% to $98.1 million, with international sales up 23.4%.
• Expense Growth: Operating expenses rose to $459.3 million from $341.0 million.
  • R&D Expenses: Increased 37.3% to $209.5 million, largely due to higher manufacturing costs ($16.3M increase) and clinical development for TPIP ($28.2M increase).
  • SG&A Expenses: Increased 67.6% to $247.3 million, driven by a $74.4 million increase in professional fees and external expenses related to BRINSUPRI commercialization.
• Non-Cash Gains: The company recorded a $47.0 million gain from the change in fair value of contingent consideration, primarily due to a decrease in share price and adjusted probabilities of success, partially offset by the reauthorization of the Priority Review Voucher (PRV) program.
• Liquidity: Cash and cash equivalents increased by $71.7 million during the quarter, despite operating cash outflows, due to net cash provided by investing activities ($265.5 million) from marketable securities maturities.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring operating losses while funding R&D for pipeline assets (TPIP, INS1148, INS1201, INS1202) and commercializing BRINSUPRI and ARIKAYCE. The company believes current cash and marketable securities ($1.22 billion combined) are sufficient to fund operations for at least the next 12 months.
• Key Milestones:
  • ARIKAYCE: Positive topline results from the Phase 3b ENCORE study were reported in March 2026. An sNDA for label expansion in the US is anticipated in the second half of 2026.
  • TPIP: Phase 3 studies for PH-ILD (PALM-ILD) and PAH (PALM-PAH) are ongoing or initiated. Data from the Phase 2b PAH open-label extension is expected in Q3 2026.
  • BRINSUPRI: Regulatory submission for Japan is accepted; a decision is anticipated in 2026.
• Risks: Key risks include the ability to successfully commercialize BRINSUPRI, obtaining full FDA approval for ARIKAYCE, reliance on third-party manufacturers, and the need for future capital raises if cash burn exceeds projections. The company also faces risks related to the reauthorization of the PRV program and potential changes in healthcare reimbursement policies.

Investor Verification Checklist

• BRINSUPRI Commercialization: Verify the sustainability of the $207M Q1 revenue run rate and the trajectory of US market penetration post-launch.
• ARIKAYCE sNDA Timing: Confirm the timeline for the sNDA submission in H2 2026 and the likelihood of label expansion to non-refractory patients.
• Cash Burn Rate: Monitor the net cash used in operating activities ($222.7M in Q1) against the $1.22B liquidity position to assess runway.
• Contingent Consideration Volatility: Note the $47M non-cash gain; verify how future stock price fluctuations and milestone probabilities will impact future earnings.
• TPIP Clinical Progress: Track enrollment and data readouts for the Phase 3 PALM-ILD and PALM-PAH studies as critical value drivers.